Lipidor AB (publ)


Kursmål for aktien: 1.00 Kr.

Det gennemsnitlige kursmål for Lipidor AB (publ) aktien er 1.00 Kr. hvilket viser forventningen til aktien indenfor de næste 12 mdr. aktien er undervurderet, da kursmålet ligger under det aktuelle aktiekurs. Aktien er undervurderet med 1.908,03 % Aktien forventes derfor at stige og være en god investering.

Om Lipidor AB (publ) aktien

Lipidor AB (publ), a pharmaceutical development company, engages in the development of drugs for the treatment of psoriasis, bacterial skin infections, and atopic dermatitis. The company develops AKP-01, which is in Phase III for the treatment of psoriasis; and preclinical stage products, such as AKP-02 for psoriasis, and AKP-03 AKP-07 for eczema. It offers active pharmaceutical ingredients used in products for various therapeutic applications, such as anti-psoriasic, antimicrobial, anti-inflammatory, antifungal, local anesthetics, non-steroidal anti-inflammatory, anti-acne, wound healing, anti-eczema, and anti-migraine. The company also develops a range of spray products for animal skin care in dogs, cats, and horses; and consumer health care products for applications, including antibacterial, antiseptic, moisturizing emollient, disinfectant, and acne and wart treatment. It has a collaboration agreement with Cannassure Therapeutics Ltd. for the development of topical medicinal cannabis products for the treatment of skin inflammations and psoriatic lesions. The company was incorporated in 2009 and is based in Danderyd, Sweden. Læs mere
Kr. 40,7M Markedsværdi (Mcap)
Kr. 1,8M Omsætning
Drug Manufacturers - General Industri
Sverige Handles på børsen Hjemmeside
Sundhed Sektor